All News

Calquence (acalabrutinib) may be a safe and effective treatment option for patients with relapsed or refractory chronic lymphocytic leukemia, according to the updated phase 2 results of an ongoing study.

Traditionally, it is the younger generations that become caregivers first. But cancer alters the best-laid plans.

Stay connected during these challenging times and keep up with all the news and updates from Susan G. Kommen Greater NYC by signing up for our latest newsletter!

Dealing with isolation is not new for widows and widowers who lost their spouses to cancer.

Save the date! We invite you to join CURE for our next monthly #CureConnect Tweet Chat on Thursday, April 30, at 1 p.m. EST, when we plan on discussing the costs of cancer.

During cancer it's easy to let friends in the "outside world" fall to the wayside, but it's sometimes possible, and helpful, to foster those relationships.

The Food and Drug Administration approved Pemazyre for the treatment of patients with previously treated, advanced cholangiocarcinoma.

The Food and Drug Administration approved Tukysa, which is indicated for use with two other drugs after patients have completed treatment with prior therapies targeting the protein HER2.

First validated prognostic score offers valuable insights for patients with chronic lymphocytic leukemia who are prescribed active surveillance.

Even with an injured trust in the world, it's important to remember the lessons that help us move through cancer and other life traumas amid the COVID-19 pandemic.

From a woman with stage 4 colon cancer deciding to stream her wedding on Zoom to a patient with breast cancer sewing masks for at-risk groups across the United States, here’s the cancer news and updates happening amid the COVID-19 pandemic.

A new genetic test that identifies patients with multiple myeloma who have high-risk genetics may help oncologists find alternative treatment options before the disease progresses.

Data from the phase 1b/2 trial of Padcev in combination with Keytruda displayed promise for patients with metastatic urothelial carcinoma, but further research is needed.

Thrivership and resilience are what we can gain from adversity and help us cope with change.

The Food and Drug Administration approved Jelmyto to treat patients with low-grade upper tract urothelial cancer.

Patients with relapsed and refractory multiple myeloma (RRMM) who had previously received multiple lines of therapy experienced a durable clinical benefit after receiving melflufen (Oncopeptides) in combination with dexamethasone.

Choosing the best path forward is hard under any circumstance, but today, those decisions are wrought with additional unknowable risks.

The adolescent and young adult cancer community is one that faces life-changing challenges at an age where this type of challenge is not expected, and it is now compounded by the COVID-19 pandemic. But there is a lifeline for AYA patients to not only cope, but thrive.

Although the new coronavirus has led to a delay in some cholangiocarcinoma trials, experts don’t expect the trials to come to an end.

COVID-19 has forced many people into a “new normal” that they aren’t familiar with and may not be equipped to handle. But cancer survivors are more prepared than most to handle the ramifications of the pandemic.

A cancer survivor describes the comparison between coping with cancer and COVID-19. Much of it is the same.

Patients who recently had lung cancer surgery are not at a higher risk for getting the new coronavirus unless they are routinely coming in and out of the hospital, according to one expert.

Immunotherapy and targeted therapy medications have brought new hope to patients with advanced disease.

The COVID-19 Pandemic has drastically altered the landscape for both oncology professionals and patients with cancer. For oncology nurse Patricia Jakel, the pandemic has altered both her professional and personal lives as an oncology professional and patient.

Cancer treatment has taught many survivors how to combat infection, a useful skill to adjusting life amid the COVID-19 pandemic.

After failing to meet its primary endpoint of progression-free survival, the JAVELIN Ovarian PARP 100 clinical trial was stopped.

The COVID-19 pandemic has forced many to shelter in place causing a rare form of isolation. One that has even challenged a group of people used to challenges, patients with cancer and survivors.

COVID-19 care may show a familiar roadmap to cancer care that some patients and caregivers wish they had.